We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PetMed Faces Concerns over New Order Sales, Competition
Read MoreHide Full Article
On Apr 6, we issued an updated research report on Pompano Beach, FL-based PetMed Express, Inc. (PETS - Free Report) . The company, operating as 1-800-PetMeds, is a leading nationwide pet pharmacy.
PetMed's shares started going downhill post the mixed fiscal third-quarter results with earnings missing the Zacks Consensus Estimate and revenues beating the same. Per the last trading price, the company lost 7.15% as against 14.21% gain of the the Zacks categorized Internet - Commerce industry over the past three months.
We are also apprehensive about the pressure on margins despite the company’s cost-reduction initiatives. Furthermore, the decline in advertising costs raise concerns.
The company operates in a highly competitive and fragmented pet medications market. PetMed is currently witnessing higher pricing pressure in the over-the-counter market due to increased competition. To address the increasing competition in the flea and tick segment, PetMed adopted a more aggressive pricing strategy that affected its gross margin.
Also the acquisition of Novartis’ animal health division by Eli Lilly and Company has posed additional challenges for PetMed. The deal combined two large pet pharmacies with Eli Lilly moving to the second position in the animal health market in terms of global revenues. Undoubtedly, this market concentration has created an anti-competitive landscape for PetMed.
In the last four quarters, the company saw a turnaround on the back of a more aggressive pricing but new order sales continued to be disappointing.
Management is currently working on issues like limited consumer spending and a change in product mix to lower-priced items, mainly generics. The company is asking veterinarians to prescribe additional brands.
The company is presently trying to implement several strategies to revive its top line. PetMed is working on improving the effectiveness of its campaigns. It has started focusing on advertising efficiency to improve new order sales and shifting sales to higher margin items, including generics while expanding product offerings.
Although the company is optimistic about the latest increase in new order sales, the sustainability of this growth is still a matter of concern. Hence, we prefer to remain on the sidelines for the time being until future data is obtained on the same.
Quidel Corporation gained 27.90% in the last one year compared with the S&P 500’s gain of 14.68%. The company reported a stellar four-quarter positive average earnings surprise of 85.97%.
Hologic jumped 20.43% in the last one year compared with the S&P 500’s gain. Its four-quarter average earnings surprise was a positive 4.16%.
Inogen gained 64.23% in the past one year, better than the S&P 500 mark. It posted a trailing four-quarter positive average earnings surprise of 49.08%.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
PetMed Faces Concerns over New Order Sales, Competition
On Apr 6, we issued an updated research report on Pompano Beach, FL-based PetMed Express, Inc. (PETS - Free Report) . The company, operating as 1-800-PetMeds, is a leading nationwide pet pharmacy.
PetMed's shares started going downhill post the mixed fiscal third-quarter results with earnings missing the Zacks Consensus Estimate and revenues beating the same. Per the last trading price, the company lost 7.15% as against 14.21% gain of the the Zacks categorized Internet - Commerce industry over the past three months.
We are also apprehensive about the pressure on margins despite the company’s cost-reduction initiatives. Furthermore, the decline in advertising costs raise concerns.
The company operates in a highly competitive and fragmented pet medications market. PetMed is currently witnessing higher pricing pressure in the over-the-counter market due to increased competition. To address the increasing competition in the flea and tick segment, PetMed adopted a more aggressive pricing strategy that affected its gross margin.
Also the acquisition of Novartis’ animal health division by Eli Lilly and Company has posed additional challenges for PetMed. The deal combined two large pet pharmacies with Eli Lilly moving to the second position in the animal health market in terms of global revenues. Undoubtedly, this market concentration has created an anti-competitive landscape for PetMed.
In the last four quarters, the company saw a turnaround on the back of a more aggressive pricing but new order sales continued to be disappointing.
Management is currently working on issues like limited consumer spending and a change in product mix to lower-priced items, mainly generics. The company is asking veterinarians to prescribe additional brands.
The company is presently trying to implement several strategies to revive its top line. PetMed is working on improving the effectiveness of its campaigns. It has started focusing on advertising efficiency to improve new order sales and shifting sales to higher margin items, including generics while expanding product offerings.
Although the company is optimistic about the latest increase in new order sales, the sustainability of this growth is still a matter of concern. Hence, we prefer to remain on the sidelines for the time being until future data is obtained on the same.
Zacks Rank & Key Picks
PetMed currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks within the broader Medical sector include Quidel Corporation (QDEL - Free Report) , Hologic, Inc. (HOLX - Free Report) , and Inogen, Inc. (INGN - Free Report) . All the three stocks sport a Zacks Rank #1(Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Quidel Corporation gained 27.90% in the last one year compared with the S&P 500’s gain of 14.68%. The company reported a stellar four-quarter positive average earnings surprise of 85.97%.
Hologic jumped 20.43% in the last one year compared with the S&P 500’s gain. Its four-quarter average earnings surprise was a positive 4.16%.
Inogen gained 64.23% in the past one year, better than the S&P 500 mark. It posted a trailing four-quarter positive average earnings surprise of 49.08%.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>